BridgeMD
CROWD-COMPARE
EU CTIS ID: 2022-503010-23-01
What this study is testing
The objective of CROWD-COMPARE is to compare the efficacy of Carvedilol and Metoprolol succinate on all-cause mortality or first hospitalization for worsening heart failure in patients followed in a heart failure clinic, who have an indication for treatment with beta-blockers due to heart failure with reduced ejection fraction.
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Patients who are registered in the Danish Heart Failure Registry with reduced ejection fraction who have claimed at least one prescription for either Carvedilol or Metoprolol succinate.
You likely can't join if
- Patients who have filled in a prescription for Carvedilol or Metoprolol succinate before the date of first registered visit in the Danish Heart Failure Registry and patients who have opted out of the study
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.